No Data
Relay Therapeutics Reports Interim Data for Breast Cancer Treatment
Relay Therapeutics Is Maintained at Overweight by Barclays
Relay Therapeutics Price Target Raised to $17.00/Share From $14.00 by Barclays
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Express News | Goldman Sachs Reinstates Buy on Relay Therapeutics, Announces $20 Price Target
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $16 to $24
103317720 : Meaning the up is not actual trend?
Newbee4 OP 103317720 : no more offering